|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis.
|
9050882 |
1997 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages.
|
10073974 |
1999 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Administration of antibody against CD154 to low-density lipoprotein receptor-deficient mice has been shown to reduce atherosclerosis and decrease T-lymphocyte and macrophage content; however, only initial lesions were studied.
|
10546000 |
1999 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In addition, abnormal expression of CD154 has been hypothesized to contribute to a wider array of diseases, from atherosclerosis to Alzheimer's disease.
|
12857968 |
2003 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The recent recognition of platelets as an abundant source of CD40L led to a reassessment of the involvement of CD40L in atherosclerosis.
|
14517846 |
2003 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Because CD40L is a potent platelet-derived cytokine that is involved in thrombosis and atherosclerosis, we evaluated the effect of GPVI-mediated release of CD40L on activation of endothelial cells.
|
15277394 |
2004 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Increasing evidence shows that CD40-CD40L interaction plays a crucial role in the pathogenesis of atherosclerosis and coronary artery disease.
|
14687897 |
2004 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
We conclude that CD40L might contribute to the initiation and progression of atherosclerosis by increasing O2*(-)- and ONOO(-)-dependent PGIS nitration and thromboxane A2/prostaglandin H2 receptor stimulation.
|
16186418 |
2005 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control.
|
15868137 |
2005 |
|
Atherosclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We investigated the role of genetic variation in CD40 and CD40L genes in subclinical atherosclerosis assessed by coronary artery calcification (CAC) and carotid intima-media thickness in 620 individuals from 230 families in the DHS.
|
16504636 |
2006 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
RGD |
Our results suggest that the expression of CD40 and CD40L in the blood cells and the activities of MMP-2 and MMP-9 in plasma were higher in As group than those in Normal group, indicating that they may contribute to the formation of atherosclerosis.
|
16317521 |
2006 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Strong evidence supports a role for CD40 ligand (CD40L) as marker and mediator of inflammatory diseases such as atherosclerosis.
|
17372166 |
2007 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
LHGDN |
The expression and potential role of platelet membrane CD154 and sCD154 in atherosclerosis was investigated in patients with peripheral arterial disease.
|
16777115 |
2007 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Several lines of evidence implicate CD40 ligand (CD40L, CD154) as a mediator and marker of atherosclerosis.
|
17332487 |
2007 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
A role for CD40-CD40L interactions has been identified in atherosclerosis, and such interactions are known to destabilize atherosclerotic plaques by inducing the expression of cytokines, chemokines, growth factors, matrix metalloproteinases and pro-coagulant factors.
|
18977174 |
2008 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
LHGDN |
Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients.
|
18787388 |
2008 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Costimulatory molecules of the tumor necrosis factor superfamily such as CD40/CD40L and OX40/OX40L have been implicated in atherosclerosis.
|
18285570 |
2008 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The CD40 receptor and its ligand (CD40L) are known to modulate both inflammation and thrombosis-2 processes important for the development and clinical expression of atherosclerosis.
|
19061720 |
2008 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The interaction between CD40 and its ligand (CD40L) has been implicated in the pathogenesis of atherosclerosis and is recognized as a central event in the development of immuno-inflammatory processes.
|
19187784 |
2009 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here, we illustrate the various functional features of these molecules, while describing the increasingly important role of CD40 in CD154-associated vascular pathologies such as atherosclerosis and atherothrombosis.
|
19282242 |
2009 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Ligands of this family comprise multiple important cytokines such as TNFα, CD40L, and interleukin-1β that promote chronic inflammatory diseases such as atherosclerosis.
|
20651286 |
2010 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
This study investigated the role of CD40L in pro-inflammatory gene expression and cellular differentiation in adipose tissue to obtain insight into mechanisms linking the MS with atherosclerosis.
|
20174757 |
2010 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
1.CD40 and CD40 ligand (CD40L) have a critical role in the pathophysiology and risk prediction of coronary artery syndrome, including atherothrombosis and atherosclerosis.
|
20456428 |
2010 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Specific inhibition of CD40L-Mac-1 binding may represent an attractive anti-inflammatory treatment strategy for atherosclerosis and other inflammatory conditions, potentially avoiding the unwanted immunologic and thrombotic effects of global inhibition of CD40L.
|
21998326 |
2011 |
|
Atherosclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Although we did not observe a significant association of CD40-CD154 gene variants with the development of CV events, an ANCOVA model adjusted for sex, age at the time of the ultrasonography assessment, follow-up time, traditional CV risk factors and anti-cyclic citrullinated peptide antibodies disclosed a significant association (p=0.0047) between CD40 rs1535045 polymorphism and carotid intima media thickness, a surrogate marker of atherosclerosis.
|
23166616 |
2012 |